Ran Tzror - Purple Biotech Independent Director
| KTOV Stock | ILA 7.40 0.60 7.50% |
Director
Mr. Ran Tzror serves as Independent Director at Kitov Pharma Ltd since March 27, 2017. He is a Member of Kitov Parent investment committee. His work experience includes the following roles Director at TyrNovo, Director at S.Y Glilot Ltd, Employee in the Corporationrationrate Business Development department at Teva Pharmaceutical Industries Limited and Senior Associate at KPMG SomekhChaikin . He holds a LLB degree, a Bachelors degree in Accounting and a MBA degree, majoring in Financial Management, all from Tel Aviv University. since 2017.
| Age | 35 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Phone | 972 3 933 3121 |
| Web | http://www.kitovpharma.com |
Purple Biotech Management Efficiency
The company has return on total asset (ROA) of (0.0915) % which means that it has lost $0.0915 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.9204) %, meaning that it generated substantial loss on money invested by shareholders. Purple Biotech's management efficiency ratios could be used to measure how well Purple Biotech manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Shmuel Rubinstein | Kamada | 78 | |
| Reem Aminoach | ICL Israel Chemicals | 58 | |
| Itzhak Krinsky | Kamada | 65 | |
| Abraham Havron | Kamada | 71 | |
| Tuvia Shoham | Kamada | 70 | |
| Ruth Ralbag | ICL Israel Chemicals | 59 | |
| Aviad Kaufman | ICL Israel Chemicals | 49 | |
| Avisar Paz | ICL Israel Chemicals | 63 | |
| Sagi Kabla | ICL Israel Chemicals | 43 | |
| Jonathan Hahn | Kamada | 32 | |
| Estery GilozRan | Kamada | 44 | |
| Ovadia Eli | ICL Israel Chemicals | 74 | |
| Gwen Melincoff | Kamada | 67 | |
| Nadav Kaplan | ICL Israel Chemicals | 74 | |
| Michael Berelowitz | Kamada | 74 | |
| Lior Reitblatt | ICL Israel Chemicals | 62 | |
Management Performance
| Return On Equity | -0.92 | |||
| Return On Asset | -0.0915 |
Purple Biotech Leadership Team
Elected by the shareholders, the Purple Biotech's board of directors comprises two types of representatives: Purple Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Purple. The board's role is to monitor Purple Biotech's management team and ensure that shareholders' interests are well served. Purple Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Purple Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Itzhak Israel, Chief Executive Officer & Director | ||
| Steven Steinberg, Independent Director | ||
| Gil BenMenachem, Vice President - Business Development | ||
| Michael Schickler, Head of Clinical Operations | ||
| CPA MBA, Strategic Director | ||
| Arie Weber, Independent Director | ||
| Bertrand Liang, Chief Medical Officer | ||
| Yisrael Gewirtz, Internal Auditor | ||
| Ran Tzror, Independent Director | ||
| Gil Efron, Deputy Chief Executive Officer, Chief Financial Officer | ||
| Simcha Rock, CFO, Director | ||
| Eric Rowinsky, Chairman of the Board | ||
| Ido Agmon, Independent Director | ||
| Gil CPA, Deputy CFO | ||
| Isaac Israel, CEO Director | ||
| Revital SternRaff, Independent Director | ||
| Avraham BenTzvi, General Counsel, Secretary | ||
| Hadas Reuveni, Founder and Chief Technology Officer of TyrNovo (a subsidiary) |
Purple Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Purple Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.92 | |||
| Return On Asset | -0.0915 | |||
| Operating Margin | (7.54) % | |||
| Shares Outstanding | 172.11 M | |||
| Shares Owned By Insiders | 0.12 % | |||
| Shares Owned By Institutions | 1.22 % | |||
| Price To Earning | (364.21) X | |||
| Price To Book | 1.27 X | |||
| Price To Sales | 16.36 X | |||
| Revenue | 1000 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Purple Stock
When determining whether Purple Biotech is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Purple Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Purple Biotech Stock. Highlighted below are key reports to facilitate an investment decision about Purple Biotech Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Purple Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Purple Stock refer to our How to Trade Purple Stock guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.